Literature DB >> 18096267

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.

Giovanna Fattovich1, Flavia Bortolotti, Francesco Donato.   

Abstract

The natural history of chronic hepatitis B virus (HBV) infection and disease is complex and highly variable. We review the natural history of chronic hepatitis B with emphasis on the rates of disease progression and factors influencing the course of the liver disease. Chronic hepatitis B is characterized by an early replicative phase (HBeAg positive chronic hepatitis) and a late low or non-replication phase with HBeAg seroconversion and liver disease remission (inactive carrier state). Most patients become inactive carriers after spontaneous HBeAg seroconversion with good prognosis, but progression to HBeAg negative chronic hepatitis due to HBV variants not expressing HBeAg occurs at a rate of 1-3 per 100 person years following HBeAg seroconversion. The incidence of cirrhosis appears to be about 2-fold higher in HBeAg negative compared to HBeAg positive chronic hepatitis. In the cirrhotic patient the 5-year cumulative risk of developing hepatocellular carcinoma is 17% in East Asia and 10% in the Western Europe and the United States and the 5-year liver related death rate is 15% in Europe and 14% in East Asia. There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096267     DOI: 10.1016/j.jhep.2007.11.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  351 in total

1.  Combination treatment in HBeAg-negative chronic hepatitis B.

Authors:  Konstantinos Tziomalos
Journal:  World J Hepatol       Date:  2009-10-31

2.  Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Syria Laperche; Christophe Hézode; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

3.  Characteristics of chronic hepatitis B patients who underwent liver biopsies.

Authors:  W Chotiyaputta; B Degertekin; B J McKenna; N Samala; R J Fontana; A S F Lok
Journal:  J Viral Hepat       Date:  2010-08-17       Impact factor: 3.728

4.  Development of Fok-I based nested polymerase chain reaction-restriction fragment length polymorphism analysis for detection of hepatitis B virus X region V5M mutation.

Authors:  Hong Kim; Seok-Hyun Hong; Seoung-Ae Lee; Jeong-Ryeol Gong; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

Review 5.  Hepatitis B therapy.

Authors:  Hellan Kwon; Anna S Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

6.  HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

Authors:  T-W Wu; C-C Chu; H-W Chang Liao; S-K Lin; T-Y Ho; M Lin; H H Lin; L-Y Wang
Journal:  Genes Immun       Date:  2013-11-28       Impact factor: 2.676

7.  Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda.

Authors:  E Seremba; J P Van Geertruyden; R Ssenyonga; C K Opio; J M Kaducu; J B Sempa; R Colebunders; P Ocama
Journal:  Vaccine       Date:  2017-04-20       Impact factor: 3.641

8.  Evaluation of storing hepatitis B vaccine outside the cold chain in the Solomon Islands: Identifying opportunities and barriers to implementation.

Authors:  Lucy Breakwell; Jenniffer Anga; Ibrahim Dadari; Nahad Sadr-Azodi; Divinal Ogaoga; Minal Patel
Journal:  Vaccine       Date:  2017-04-18       Impact factor: 3.641

9.  Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors:  Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

Review 10.  HIV/HBV coinfection in children and antiviral therapy.

Authors:  Sara A Healy; Sonia Gupta; Ann J Melvin
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.